Lipopeptide vaccines - EQiTX

Drug Profile

Lipopeptide vaccines - EQiTX

Alternative Names: VacTX

Latest Information Update: 12 Nov 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EQiTX
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Autoimmune disorders; Bacterial infections; Cancer; Hypersensitivity; Prostate cancer; Viral infections

Most Recent Events

  • 21 Mar 2006 Phase-I clinical trials in Viral infections in Australia (unspecified route)
  • 03 Aug 2005 This programme is available for licensing (http://www.eqitx.com)
  • 03 Aug 2005 Early research in Allergy in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top